key: cord-0705365-c52vdze1
authors: Razonable, Raymund R.; Marshall, William F.; Stevens, Ryan W.; Kumar, Shaji; Murad, M. Hassan; Wilson, Walter R.
title: Mayo Clinic Strategies for COVID-19 Rapid Appraisal System for COVID-19 Medical Information
date: 2020-06-22
journal: Mayo Clin Proc
DOI: 10.1016/j.mayocp.2020.05.042
sha: 7f92dc440bce800913b3a1b1215faf92d3cb66f9
doc_id: 705365
cord_uid: c52vdze1

nan

At the time of this writing, COVID-19 has affected 3.5 million people worldwide and caused over 248,000 deaths.

Because COVID-19 is a novel disease, not much is known about its epidemiology, clinical course, treatment, and outcomes. As a result, medical providers around the world have grappled with how best to manage the pandemic. Over the 4 months since the disease was reported, medical information has increased rapidly and exponentially about SARS-CoV-2 and COVID-19.

The paucity of baseline knowledge and clinical experience coupled with the rapid pace of new literature reported on SARS-CoV-2 and COVID-19 is overwhelming medical providers who have reported mental fatigue amid the information overload. The premature opinions voiced in the lay press and social media have added further confusion, as they are often not accompanied by sound interpretation of, for example, a study's methodology and findings. Whereas many reports have been useful in the clinical care of patients, the publication of prerelease (preprint), non-peer-reviewed papers has, at times, increased the risk of harmful outcomes and adverse drug events.

To better guide our medical providers, we created a Rapid Literature Review Task Force to streamline our process of assessing the rapidly expanding medical information about COVID-19. The classic 4A's approach (Ask, Acquire, Appraise, Apply) that was proposed in the early days of the evidence-based medicine movement captures the methods of this task force (Figure) .

First, we defined the primary goal of the Rapid Literature Review Task Force, which was to provide guidance to our clinical practice by comprehensively and meaningfully assessing the rapidly expanding COVID-19 literature. We engaged stakeholders from within and outside our division including faculty, fellows, pharmacists, and allied health. We also sought diversity among the membership to ensure that the different aspects of COVID-19 were represented-from epidemiology to infection prevention and control, diagnostics, therapeutics, clinical care, and public health issues, among others.

Second, we established key relevant questions that guided our work, such as the following: How is SARS-CoV-2 transmitted? What are prevention strategies and critical ways to preserve personal protective equipment? What is the role of antimicrobials as preventive and treatment measures? How do we best manage COVID-19? What is the role of asymptomatic individuals in the spread of the disease? Subgroups were created, assigned to each of the major topics, and tasked with rapidly reviewing and compiling existing literature at the time the Rapid Literature Review Task Force was formed and, in real time, the evolving literature on their assigned topics. Priority was given to appraising peer-reviewed COVID-19 literature published in high-impact journals. We also involved a medical librarian, which was key to helping subgroups identify relevant literature and screen out publications that were unlikely to be impactful. 

The Rapid Literature Review Task Force contributed relevant information to different sectors of our pandemic response-from infection prevention and control to diagnostic guidance and clinical management, among others. [3] [4] [5] Careful review of the rapidly evolving literature allowed for the contribution of solid and relevant findings to groups tasked with developing institutional guidelines for the prevention, diagnosis, and management of COVID-19. [3] [4] [5] The clinical and management guidance was initially shared within the institution through its publication on the internal infectious diseases division webpage and was subsequently built into the system's internal platform for guidelines, clinical pathways, and care process models (eg, AskMayoExpert). 3 This allowed for findings from the Rapid Literature Review Task Force to be integrated into the clinical practice through widespread dissemination to medical providers and other end users, both within our health enterprise and beyond our walls.

The content of the guidance continues to be enhanced and expanded as new information becomes available. By carefully assessing the extensive available and emerging literature, the output of the Rapid Literature Review Task Force has optimized the institutional response to this pandemic and provided clinicians with a usable framework for provision of individual patient care.

In conclusion, the rapid publication of medical information on the viral pandemic required an equally rapid review and appraisal of its relevance in our clinical practice.

We applied a systematic approach to adequately and comprehensively appraise and apply the literature. Multidisciplinary collaboration is necessary to leverage everyone's expertise-specifically, partnership among the data analysts and clinical experts has been instrumental to the success of this group's task in contributing to the institutional pandemic response.

A framework for evidence synthesis programs to respond to a pandemic

Clinical Practice Guidelines: A Primer on Development and Dissemination

Treatment considerations for COVID-19: a critical review of the evidence (or lack thereof)

A collaborative multidisciplinary approach to the management of coronavirus disease-19 in the hospital setting

Editing, proofreading, and reference verification were provided by Scientific Publications, Mayo Clinic.